Trial Profile
Sitravatinib (MGCD516) and Nivolumab in Oral Cavity Cancer Window Opportunity Study (SNOW)
Status:
Completed
Phase of Trial:
Phase 0
Latest Information Update: 31 Jul 2023
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary) ; Sitravatinib (Primary)
- Indications Mouth neoplasm; Oropharyngeal cancer; Squamous cell cancer
- Focus Biomarker; Pharmacodynamics; Proof of concept
- Acronyms SNOW
- 30 Mar 2021 Status changed from recruiting to completed.
- 31 May 2020 Results (n=10) presented at the 56th Annual Meeting of the American Society of Clinical Oncology
- 04 May 2020 Status changed from active, no longer recruiting to recruiting.